PMC:7352545 / 71521-72675 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T694","span":{"begin":0,"end":6},"obj":"Body_part"},{"id":"T695","span":{"begin":267,"end":273},"obj":"Body_part"},{"id":"T696","span":{"begin":1013,"end":1021},"obj":"Body_part"},{"id":"T697","span":{"begin":1035,"end":1038},"obj":"Body_part"},{"id":"T698","span":{"begin":1039,"end":1046},"obj":"Body_part"},{"id":"T699","span":{"begin":1098,"end":1101},"obj":"Body_part"},{"id":"T700","span":{"begin":1141,"end":1144},"obj":"Body_part"}],"attributes":[{"id":"A694","pred":"fma_id","subj":"T694","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A695","pred":"fma_id","subj":"T695","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A696","pred":"fma_id","subj":"T696","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A697","pred":"fma_id","subj":"T697","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A698","pred":"fma_id","subj":"T698","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A699","pred":"fma_id","subj":"T699","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A700","pred":"fma_id","subj":"T700","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T276","span":{"begin":122,"end":127},"obj":"Disease"}],"attributes":[{"id":"A276","pred":"mondo_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1034","span":{"begin":0,"end":6},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T1035","span":{"begin":82,"end":85},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T1036","span":{"begin":267,"end":273},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T1037","span":{"begin":389,"end":394},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T1038","span":{"begin":395,"end":405},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1039","span":{"begin":705,"end":710},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T1040","span":{"begin":859,"end":864},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T1041","span":{"begin":1007,"end":1012},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T1042","span":{"begin":1064,"end":1065},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T1043","span":{"begin":1135,"end":1140},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52765","span":{"begin":351,"end":360},"obj":"Chemical"},{"id":"T58339","span":{"begin":411,"end":420},"obj":"Chemical"},{"id":"T419","span":{"begin":445,"end":455},"obj":"Chemical"},{"id":"T44677","span":{"begin":476,"end":481},"obj":"Chemical"},{"id":"T42308","span":{"begin":582,"end":587},"obj":"Chemical"},{"id":"T422","span":{"begin":630,"end":634},"obj":"Chemical"},{"id":"T423","span":{"begin":903,"end":905},"obj":"Chemical"},{"id":"T424","span":{"begin":906,"end":908},"obj":"Chemical"},{"id":"T37578","span":{"begin":909,"end":912},"obj":"Chemical"},{"id":"T428","span":{"begin":1013,"end":1021},"obj":"Chemical"}],"attributes":[{"id":"A88714","pred":"chebi_id","subj":"T52765","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A87228","pred":"chebi_id","subj":"T58339","obj":"http://purl.obolibrary.org/obo/CHEBI_22315"},{"id":"A72109","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_26873"},{"id":"A47883","pred":"chebi_id","subj":"T44677","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A64776","pred":"chebi_id","subj":"T42308","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A25199","pred":"chebi_id","subj":"T422","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A58596","pred":"chebi_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A46077","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_55460"},{"id":"A84125","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_74861"},{"id":"A43174","pred":"chebi_id","subj":"T37578","obj":"http://purl.obolibrary.org/obo/CHEBI_17115"},{"id":"A29241","pred":"chebi_id","subj":"T37578","obj":"http://purl.obolibrary.org/obo/CHEBI_29999"},{"id":"A9776","pred":"chebi_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T130","span":{"begin":749,"end":759},"obj":"http://purl.obolibrary.org/obo/GO_0004175"},{"id":"T131","span":{"begin":1109,"end":1118},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}

{"project":"LitCovid-sentences","denotations":[{"id":"T692","span":{"begin":0,"end":73},"obj":"Sentence"},{"id":"T693","span":{"begin":74,"end":164},"obj":"Sentence"},{"id":"T694","span":{"begin":165,"end":208},"obj":"Sentence"},{"id":"T695","span":{"begin":209,"end":336},"obj":"Sentence"},{"id":"T696","span":{"begin":337,"end":456},"obj":"Sentence"},{"id":"T697","span":{"begin":457,"end":560},"obj":"Sentence"},{"id":"T698","span":{"begin":561,"end":692},"obj":"Sentence"},{"id":"T699","span":{"begin":693,"end":728},"obj":"Sentence"},{"id":"T700","span":{"begin":729,"end":765},"obj":"Sentence"},{"id":"T701","span":{"begin":766,"end":933},"obj":"Sentence"},{"id":"T702","span":{"begin":934,"end":950},"obj":"Sentence"},{"id":"T703","span":{"begin":951,"end":1022},"obj":"Sentence"},{"id":"T704","span":{"begin":1023,"end":1154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}

{"project":"2_test","denotations":[{"id":"32604730-30684561-51944107","span":{"begin":331,"end":334},"obj":"30684561"},{"id":"T85859","span":{"begin":331,"end":334},"obj":"30684561"}],"text":"Plasma sera prepared from infected patients is an alternative medication. The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. In addition, Mab therapy is another option. For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. They target human ACE2, PLpro (PDB: 3e9s), the CoV main proteinase (PDB: 6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. CoV 3CLpro (PDB: 6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template."}